| Revenue growth | 39.7% YoY in INR terms. |
|---|---|
| Margins | EBITDA margin at 16.9%; aiming to restore to historical levels. |
| Order book | Active client base expanded to 105; 14 sequential additions. |
| Demand visibility | Sustained demand across top 20 accounts; healthy Net Revenue Retention. |
| Management confidence | Strong start to FY27; strongest Q1 sequential growth in four years. |
Growth
Revenue grew 39.7% YoY in INR and 26.5% in USD; PAT grew 45.9% QoQ but remained flat YoY.
Outlook
Management expects operating leverage to improve and profitability to strengthen in H2 FY27 as investments mature.
Risks
PAT margin compression (10.9% vs 15.3% YoY); high dependence on Biopharma sector (91.6% of revenue).
Last quarter's promises, checked
Delivered
- Guided Q4 revenue ₹10,000M → delivered ₹10,000M (= BEAT)
- Guided FY26 revenue >₹3,500 Cr → delivered ₹3,510.5 Cr (= BEAT)
- Guided 12.5% dividend increase → delivered ₹2.25/share (= BEAT)
Partly delivered
- Guided EBITDA margin recovery in FY27 → delivered 16.9% in Q1 (= PARTIAL)
- Guided debtor days 60-70 → delivered 63 days (= BEAT)
Missed
- Guided PAT growth → delivered 1.4% decline YoY (= MISS)
Investor Presentation filed with BSE, NSE: INDGN. Summary written with AI assistance from the document.
Indegene Ltd: key numbers
- Share price
- ₹598.40
- Market cap
- ₹14,416 Cr
- Revenue (annual)
- ₹3,510 Cr
- Net profit (annual)
- ₹401.1 Cr
- P/E (TTM)
- 36.0×Sector 53.1×
- Promoter holding
- 0.00%+0.00% QoQ
- FII holding
- 9.92%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Indegene Ltd
All →Indegene Business Update
Indegene Limited hosted its Indegene Digital Summit 2026, focusing on operationalizing AI within life sciences. The event also featured the presentation of the VITAL Awards 2026.
Indegene Merger & Restructuring
Indegene Limited completed the internal merger of its two indirect wholly owned subsidiaries in Germany. This reorganization does not impact Indegene's financial position or operations.
Indegene Legal & Regulatory
Indegene Limited received preliminary court approval for a class action settlement related to the U.S. Telephone Consumer Protection Act. Final hearing is scheduled for January 2027.
Indegene Legal & Regulatory
The U.S. Court preliminarily approved the class action settlement for Indegene's subsidiary. The maximum settlement fund is approximately ₹44.84 Crore.
- Value
- ₹44.84 Cr
Indegene Legal & Regulatory
Indegene Limited's subsidiary, Indegene Inc., finalized a class-action settlement framework regarding U.S. fax communication violations. The maximum potential settlement fund is USD 4.72 million (₹44.84 Crore).
- Value
- ₹44.84 Cr
Indegene Legal & Regulatory
Indegene Limited's subsidiary finalized a USD 4.72 million class-action settlement agreement regarding U.S. TCPA violations. The settlement, involving approximately 18,851 unique fax numbers, remains subject to court approval.
- Value
- ₹45.24 Cr